vs
MINERALS TECHNOLOGIES INC（MTX）とRevvity（RVTY）の財務データ比較。上の社名をクリックして会社を切り替えられます
Revvityの直近四半期売上が大きい（$772.1M vs $519.5M、MINERALS TECHNOLOGIES INCの約1.5倍）。Revvityの純利益率が高く（12.7% vs 7.2%、差は5.6%）。Revvityの前年同期比売上増加率が高い（5.9% vs 0.3%）。Revvityの直近四半期フリーキャッシュフローが多い（$161.8M vs $31.9M）。過去8四半期でRevvityの売上複合成長率が高い（9.0% vs -1.4%）
コンパスミネラルズインターナショナルは米国の上場企業で、塩、塩化マグネシウム、硫酸カリウムなどの鉱物の大手生産者であり、本社はカンザス州オーバーランドパークに所在する。北米と英国の顧客に道路除氷用のバルク塩を提供するほか、世界中の栽培者に植物栄養製品を供給し、一般向け除氷製品、水処理製品、民生・業務用の関連鉱物製品も生産している。
レブィティ（Revvity, Inc.）は米国のライフサイエンス・診断事業を手がける企業で、製薬およびバイオテクノロジー業界を主な顧客とし、特に新たな細胞治療や遺伝子治療の開発に関連するサービス・製品を提供している。前身は多岐にわたる事業を展開してきた老舗企業パーキンエルマーである。
MTX vs RVTY — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $519.5M | $772.1M |
| 純利益 | $37.2M | $98.4M |
| 粗利率 | 24.0% | — |
| 営業利益率 | 11.9% | 14.5% |
| 純利益率 | 7.2% | 12.7% |
| 売上前年比 | 0.3% | 5.9% |
| 純利益前年比 | -31.1% | 3.9% |
| EPS（希薄化後） | $1.11 | $0.86 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $519.5M | $772.1M | ||
| Q3 25 | $532.4M | $698.9M | ||
| Q2 25 | $528.9M | $720.3M | ||
| Q1 25 | $491.8M | $664.8M | ||
| Q4 24 | $518.1M | $729.4M | ||
| Q3 24 | $524.7M | $684.0M | ||
| Q2 24 | $541.2M | $691.7M | ||
| Q1 24 | $534.5M | $649.9M |
| Q4 25 | $37.2M | $98.4M | ||
| Q3 25 | $43.0M | $46.7M | ||
| Q2 25 | $45.4M | $53.9M | ||
| Q1 25 | $-144.0M | $42.2M | ||
| Q4 24 | $54.0M | $94.6M | ||
| Q3 24 | $46.7M | $94.4M | ||
| Q2 24 | $19.7M | $55.4M | ||
| Q1 24 | $46.7M | $26.0M |
| Q4 25 | 24.0% | — | ||
| Q3 25 | 25.7% | 53.6% | ||
| Q2 25 | 25.9% | 54.5% | ||
| Q1 25 | 24.3% | 56.5% | ||
| Q4 24 | 25.6% | — | ||
| Q3 24 | 25.8% | 56.3% | ||
| Q2 24 | 26.6% | 55.7% | ||
| Q1 24 | 25.4% | 54.6% |
| Q4 25 | 11.9% | 14.5% | ||
| Q3 25 | 13.3% | 11.7% | ||
| Q2 25 | 14.1% | 12.6% | ||
| Q1 25 | -32.6% | 10.9% | ||
| Q4 24 | 16.2% | 16.3% | ||
| Q3 24 | 14.6% | 14.3% | ||
| Q2 24 | 9.3% | 12.4% | ||
| Q1 24 | 14.1% | 6.8% |
| Q4 25 | 7.2% | 12.7% | ||
| Q3 25 | 8.1% | 6.7% | ||
| Q2 25 | 8.6% | 7.5% | ||
| Q1 25 | -29.3% | 6.4% | ||
| Q4 24 | 10.4% | 13.0% | ||
| Q3 24 | 8.9% | 13.8% | ||
| Q2 24 | 3.6% | 8.0% | ||
| Q1 24 | 8.7% | 4.0% |
| Q4 25 | $1.11 | $0.86 | ||
| Q3 25 | $1.37 | $0.40 | ||
| Q2 25 | $1.44 | $0.46 | ||
| Q1 25 | $-4.51 | $0.35 | ||
| Q4 24 | $1.67 | $0.77 | ||
| Q3 24 | $1.45 | $0.77 | ||
| Q2 24 | $0.61 | $0.45 | ||
| Q1 24 | $1.44 | $0.21 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $332.6M | $919.9M |
| 総負債低いほど良い | $961.3M | — |
| 株主資本純資産 | $1.7B | $7.3B |
| 総資産 | $3.5B | $12.2B |
| 負債/資本比率低いほどレバレッジが低い | 0.56× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $332.6M | $919.9M | ||
| Q3 25 | $328.3M | $931.4M | ||
| Q2 25 | $319.9M | $991.8M | ||
| Q1 25 | $312.2M | $1.1B | ||
| Q4 24 | $337.1M | $1.2B | ||
| Q3 24 | $324.5M | $1.2B | ||
| Q2 24 | $316.4M | $2.0B | ||
| Q1 24 | $320.1M | $1.7B |
| Q4 25 | $961.3M | — | ||
| Q3 25 | $964.3M | — | ||
| Q2 25 | $965.6M | — | ||
| Q1 25 | $966.7M | — | ||
| Q4 24 | $966.1M | — | ||
| Q3 24 | $922.9M | — | ||
| Q2 24 | $922.4M | — | ||
| Q1 24 | $925.8M | — |
| Q4 25 | $1.7B | $7.3B | ||
| Q3 25 | $1.7B | $7.4B | ||
| Q2 25 | $1.7B | $7.6B | ||
| Q1 25 | $1.6B | $7.6B | ||
| Q4 24 | $1.7B | $7.7B | ||
| Q3 24 | $1.7B | $7.9B | ||
| Q2 24 | $1.7B | $7.9B | ||
| Q1 24 | $1.7B | $7.8B |
| Q4 25 | $3.5B | $12.2B | ||
| Q3 25 | $3.5B | $12.1B | ||
| Q2 25 | $3.5B | $12.4B | ||
| Q1 25 | $3.4B | $12.4B | ||
| Q4 24 | $3.4B | $12.4B | ||
| Q3 24 | $3.4B | $12.8B | ||
| Q2 24 | $3.3B | $13.4B | ||
| Q1 24 | $3.3B | $13.4B |
| Q4 25 | 0.56× | — | ||
| Q3 25 | 0.58× | — | ||
| Q2 25 | 0.58× | — | ||
| Q1 25 | 0.60× | — | ||
| Q4 24 | 0.55× | — | ||
| Q3 24 | 0.54× | — | ||
| Q2 24 | 0.55× | — | ||
| Q1 24 | 0.56× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $64.3M | $182.0M |
| フリーキャッシュフロー営業CF - 設備投資 | $31.9M | $161.8M |
| FCFマージンFCF / 売上 | 6.1% | 21.0% |
| 設備投資強度設備投資 / 売上 | 6.2% | 2.6% |
| キャッシュ転換率営業CF / 純利益 | 1.73× | 1.85× |
| 直近12ヶ月FCF直近4四半期 | $86.6M | $509.4M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $64.3M | $182.0M | ||
| Q3 25 | $70.9M | $138.5M | ||
| Q2 25 | $62.9M | $134.3M | ||
| Q1 25 | $-4.4M | $128.2M | ||
| Q4 24 | $70.4M | $174.2M | ||
| Q3 24 | $60.0M | $147.9M | ||
| Q2 24 | $50.1M | $158.6M | ||
| Q1 24 | $55.9M | $147.6M |
| Q4 25 | $31.9M | $161.8M | ||
| Q3 25 | $43.6M | $120.0M | ||
| Q2 25 | $33.8M | $115.5M | ||
| Q1 25 | $-22.7M | $112.2M | ||
| Q4 24 | $42.3M | $149.8M | ||
| Q3 24 | $35.3M | $125.6M | ||
| Q2 24 | $29.9M | $136.6M | ||
| Q1 24 | $39.4M | $129.7M |
| Q4 25 | 6.1% | 21.0% | ||
| Q3 25 | 8.2% | 17.2% | ||
| Q2 25 | 6.4% | 16.0% | ||
| Q1 25 | -4.6% | 16.9% | ||
| Q4 24 | 8.2% | 20.5% | ||
| Q3 24 | 6.7% | 18.4% | ||
| Q2 24 | 5.5% | 19.7% | ||
| Q1 24 | 7.4% | 20.0% |
| Q4 25 | 6.2% | 2.6% | ||
| Q3 25 | 5.1% | 2.6% | ||
| Q2 25 | 5.5% | 2.6% | ||
| Q1 25 | 3.7% | 2.4% | ||
| Q4 24 | 5.4% | 3.4% | ||
| Q3 24 | 4.7% | 3.3% | ||
| Q2 24 | 3.7% | 3.2% | ||
| Q1 24 | 3.1% | 2.7% |
| Q4 25 | 1.73× | 1.85× | ||
| Q3 25 | 1.65× | 2.97× | ||
| Q2 25 | 1.39× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | 1.30× | 1.84× | ||
| Q3 24 | 1.28× | 1.57× | ||
| Q2 24 | 2.54× | 2.87× | ||
| Q1 24 | 1.20× | 5.67× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
MTX
| High Temperature Technologies | $178.0M | 34% |
| Specialty Additives | $141.8M | 27% |
| Household And Personal Care | $132.5M | 26% |
| Environmental And Infrastructure | $67.2M | 13% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
